Cytosorbents’ (CTSO) Buy Rating Reiterated at D. Boral Capital

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating restated by D. Boral Capital in a research note issued on Thursday,Benzinga reports. They currently have a $10.00 price target on the medical research company’s stock.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Cytosorbents in a report on Friday, January 9th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Cytosorbents presently has an average rating of “Hold” and a consensus target price of $5.38.

Cytosorbents Price Performance

Shares of NASDAQ CTSO traded down $0.06 during trading on Thursday, hitting $0.61. The company had a trading volume of 162,080 shares, compared to its average volume of 80,309. The firm has a market capitalization of $38.56 million, a price-to-earnings ratio of -3.41 and a beta of 1.36. The stock has a fifty day simple moving average of $0.69 and a two-hundred day simple moving average of $0.76. The company has a quick ratio of 1.71, a current ratio of 2.11 and a debt-to-equity ratio of 1.61. Cytosorbents has a fifty-two week low of $0.50 and a fifty-two week high of $1.39.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. lifted its stake in shares of Cytosorbents by 149.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after purchasing an additional 37,519 shares during the last quarter. Avenir Corp raised its holdings in Cytosorbents by 0.3% in the 2nd quarter. Avenir Corp now owns 5,058,537 shares of the medical research company’s stock valued at $6,475,000 after buying an additional 13,619 shares during the period. Vanguard Group Inc. lifted its position in Cytosorbents by 3.7% in the third quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after buying an additional 79,535 shares during the last quarter. GSA Capital Partners LLP purchased a new position in Cytosorbents during the third quarter worth about $105,000. Finally, CM Management LLC boosted its stake in Cytosorbents by 3.1% during the third quarter. CM Management LLC now owns 1,288,128 shares of the medical research company’s stock worth $1,203,000 after buying an additional 38,128 shares during the period. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.